|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
ATE173159T1
(de)
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
CA2290624C
(en)
|
1997-06-06 |
2006-12-05 |
John W. Shell |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
CA2389236A1
(en)
|
1999-11-02 |
2001-05-10 |
Depomed, Inc. |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
ES2270982T3
(es)
|
2000-02-04 |
2007-04-16 |
Depomed, Inc. |
Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
JP2004532259A
(ja)
|
2001-05-29 |
2004-10-21 |
デポメッド ディベロップメント リミティド |
胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
ES2232302B1
(es)
|
2003-11-07 |
2006-08-01 |
Universitat De Les Illes Balears |
Myo-inositol hexafosfato para uso topico.
|
|
ES2288126B2
(es)
|
2006-06-01 |
2009-07-06 |
Universitat De Les Illes Balears |
Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
|
|
ES2332636B1
(es)
|
2008-08-06 |
2011-02-10 |
Universitat De Les Illes Balears |
Composicion de liquido de dialisis.
|
|
CN105949234B
(zh)
|
2011-09-29 |
2018-07-10 |
苏黎世联邦理工学院 |
用于治疗艰难梭菌感染的药物化合物
|
|
EP2579036A1
(en)
|
2011-10-06 |
2013-04-10 |
Laboratorios Sanifit, S.L. |
Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
|
|
ES2495666B1
(es)
*
|
2013-03-15 |
2015-08-10 |
Laboratoris Sanifit, S.L. |
Uso de derivados con enlaces c-o-p en pacientes con fallo renal
|
|
US9364490B2
(en)
*
|
2013-03-15 |
2016-06-14 |
Laboratoris Sanifit, S.L. |
Use of derivatives containing C—O—P bonds in patients with kidney failure
|
|
DK3386994T3
(da)
|
2015-12-11 |
2020-01-13 |
Eth Zuerich |
4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion
|
|
EA037572B1
(ru)
|
2015-12-11 |
2021-04-15 |
Этх Цюрих |
Производные инозитола для применения в патологической кристаллизации
|